The effects of heparinized normal saline flushing and prophylactic enoxaparin on central venous catheter thrombosis in PICU hospitalized pediatric
Abstract
Background: Central venous catheter (CVC) thrombosis is one of the most common complications of CVC that occurs in children and adults. Prevention of this blockage improves the treatment process and reduces treatment costs. Due to the lack of studies on preventive methods of CVC thrombosis, this study aimed to examine the effect of NS flushing heparinized and prophylactic dose of enoxaparin in prevention of CVC induced thrombosis in hospitalized patients in pediatric intensive care unit (PICU).
Methods: Eighty pediatrics with Central venous catheter admitted to the PICU enrolled in this trial and were divided into two groups as receiving heparinized normal saline was flushed every 8 hours under sterile conditions and receiving enoxaparin trough injection subcutaneously every 12 hours. The incidence of CVC-related thrombosis, diagnosed using color Doppler ultrasound of the vein containing the catheter was measured. Patients were monitored daily in terms of clinical symptoms related to thrombosis.
Results: There was no statistically significant difference in gender, age, anthropometric findings and vital sign as well as risk factors between two groups of the trial (P>0.05). Additionally, the finding showed a statistically significant relationship between major surgery (P=0.01) and heart disease (P=0.03) with symptomatic and asymptomatic thrombosis between the enoxaparin and heparinized normal saline groups. The rate of sepsis and bleeding were lower in enoxaparin group but it was not significant between study groups.
Conclusion: These findings indicate that enoxaparin may be considered as a clinical approach in thrombosis management and more clinical trials are needed.
[2] Merrer J, De Jonghe B, Golliot F, Lefrant J-Y, Raffy B, Barre E, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. Jama. 2001; 286(6):700-7.
[3] Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia: CRC Press. 2007; 93-142.
[4] Björkander M, Bentzer P, Schött U, Broman ME, Kander T. Mechanical complications of central venous catheter insertions: A retrospective multicenter study of incidence and risks. Acta Anaesthesiol Scand. 2019; 63(1):61-8.
[5] Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011; 9:316-24.
[6] Karen E. A critical review of thromboembolic complications associated with central venous catheters. Canadian Journal of Anesthesia. 2008; 55(8):532.
[7] Jacobs BR. Central venous catheter occlusion and thrombosis. Crit Care Clin. 2003; 19(3):489-514.
[8] Randolph AG. An evidence-based approach to central venous catheter management to prevent catheter-related infection in critically ill patients. Crit Care Clin. 1998; 14(3):411-21.
[9] Keogh S. Keeping IVs working. Qld Nurse. 2013; 32(2):31.
[10] Bishop L. Aftercare and management of central venous access devices. Central venous catheters. 2009; 221-37.
[11] Lopez-Briz E, Garcia VR, Cabello JB, Bort-Marti S, Sanchis RC. Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. Cochrane Database Syst Rev. 2022; 7(7).
[12] Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia: CRC Press. 2012; 36-88.
[13] Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of heparin and related drugs. Pharmacological reviews. 2016; 68(1):76-141.
[14] Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2):e737S-e801S.
[15] Pelland-Marcotte M-C, Amiri N, Avila ML, Brandão LR. Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children. Cochrane Database Syst Rev. 2020; 6(6).
[16] Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res. 2003; 109(2-3):101-8.
[17] Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, et al. THROMBOTECT–a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019; 104(4):756-65.
[18] Klein J, Jepsen A, Patterson A, Reich RR, Mason TM. Heparin Versus Normal Saline: Flushing Effectiveness in Managing Central Venous Catheters in Patients Undergoing Blood and Marrow Transplantation. Clin J Oncol Nurs. 2018; 22(2):199-202.
[19] Bradford NK, Edwards RM, Chan RJ. Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long-term central venous catheters in infants and children. Cochrane Database Syst Rev. 2020; 4(4):CD010996.
| Files | ||
| Issue | Article in Press |
|
| Section | Research Article(s) | |
| Keywords | ||
| Heparin Enoxaparin Thrombosis PICU Central venous catheter Pediatric | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
